Name of the trial? Abbvie M23-362
What type of cancer is this for? Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (previously Gr 1-3a)
Phase of trial? Phase 2
Who is this trial for? Previously treated Follicular Lymphoma, Now B-cell lymphoma. Relapsed or refractory Follicular Lymphoma.
What biomarkers are involved? None
What is the National Clinical Trial #? NCT05451810
Summary of the trial: A study to evaluate adverse events of subcutaneous (injection) Epcoritamab, administered in the outpatient setting.
Need to know information: For relapsed/refractory Diffuse Large B-cell Lymphoma, previously treated with at least 1 line of systemic chemotherapy. Can have either failed prior transplant or was overage for transplant. For Relapsed/Refractory Follicular Lymphoma, previously treated with at least 2 lines of therapy, including 1 monoclonal antibody, previously treated with chemotherapy or lenalidomide. Have progressed on the last prior line of therapy. This trial is open at all Cancer and Hematology sites, however, the first 2 cycles must be done at our main location in downtown Grand Rapids.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
NAME: ACERTA ESCALADE
What kind of cancer is this for? Diffuse Large B-Cell lymphoma.
Phase: III
Who is this trial for? Men and women who are younger than or equal to 75 years old with lymphoma that has never been treated before.
What biomarkers are involved? None
What is National Clinical Trial #? NCT04529772
Brief summary of trial: This trial is looking to see if the study drug (acalabrutinib) added to RCHOP (chemo plan) works better than RCHOP and a harmless drug.
Need to know: You must be younger or equal to 75 years old and your cancer cell type must be non-germinal center B-cell lymphoma.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Olympia-2, R1979-ONC-2075
What type of cancer is this trial for? Untreated Follicular Lymphoma
Trial Phase: 3
Who is this trial for? This trial is for newly diagnosed or untreated patients with Follicular Lymphoma.
What biomarkers are required for eligibility? CD20+ Follicular Lymphoma
National Clinical Trial #? NCT06097364
Brief Summary of the trial: This trial is looking at how well a new drug Odronextamb combined with Chemotherapy works, and the safety of drug compared to Rituximab (already approved treatment)and Chemotherapy for follicular lymphoma.
Need to know: Must have not had any previous treatment for follicular lymphoma.
Where is this trial available? The Cancer and Hematology Centers and other various sites across the country. Please click on link above for more information.
For more information, please call 616-975-3065 or email [email protected]